ClinicalTrials.gg
RecruitingNCT07322380FEDERATEUpdated Nov 17, 2026

Feasibility and Adoption of a Screening Program for T1D Relatives in Canada

An interventional study of Centralized Monitoring Approach and Decentralized Monitoring Approach in Type 1 Diabetes (T1D), sponsored by Institut de Recherches Cliniques de Montreal. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Institut de Recherches Cliniques de Montreal · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 17, 2026Now RecruitingFirst site in Canada+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal — 8 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Institut de Recherches Cliniques de Montreal.

Planned enrollment
Largest of 38
1,000 · median 29
Started
2026
with 4 others
No phase
17 of 42
6 open now
Registered
38th of 42
by date

Among the 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal, this one has the largest planned enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2026, is one of 17 with no phase, and was the 38th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

8 of the 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Diabetes Mellitus, Type 1 by Institut de Recherches Cliniques de Montreal, or all of them as a file.
02

Study summary

The aim of this study will be to evaluate the feasibility of an autoantibody-based type 1 diabetes screening program for first degree relatives of people living with type 1 diabetes within the province of Quebec. Feasibility of follow-up strategies of "at-risk" individuals will also be assessed.

This project will be divided into two phases, with the aim to evaluate:

  1. The feasibility of a IAb (islet antibody)-based screening process for first degree relatives of people living with type 1 diabetes (T1D).
  2. The feasibility of two approaches for follow-up monitoring in case of positive screening: centralized (within the organization) and decentralized approach (relying on individuals' healthcare providers), in the Quebec province setting.

Participants will come to the laboratory for blood sample collection, medical history and genetic risk score assessment, as well as anthropometric and cutaneous advanced glycated end (AGE) products measurements. A series of questionnaires will be completed.

After screening results are obtained (i.e., presence or absence of IAbs), a virtual visit will be conducted to communicate results to participants.

A positive result for IAb will warrant a second test for confirmation , using WBD within 3 months of initial screening.

After IAb positivity confirmation, participants will be invited to participate in phase 2 of this project (monitoring). Participants will be given the opportunity to select either a centralized or decentralized path for study monitoring.

Follow-up will be dependent of the stage of T1D:

  • Participants in pre-stage 1 or stage 1 (2 or more positive IAbs without dysglycemia) T1D will receive a follow-up phone call six months after the initial screening.
  • Participants in stage 2 (2 or more positive IAbs with dysglycemia) will be contacted one month after screening.
03

Conditions studied

  • Type 1 Diabetes (T1D)

Keywords

  • screening
  • type 1 diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females ≥18 years old living in the Québec province
  • Having a FDR living with T1D (parents, siblings or offspring)
  • Willing to adhere to follow-up care if screened positive

Exclusion criteria

Exclusion Criteria:

  • Having a diagnosis of T1D
  • Pregnancy (ongoing or current attempt to become pregnant)
  • Current or future expected use of medication (except low stable dose and inhaled steroids and stable adrenal insufficiency treatment e.g., Cortef®) or any systemic agents
  • Planned or recent (\< 6 weeks) monoclonal antibodies treatment, immunoglobulin perfusions or plasmapheresis.
  • Other serious medical illness likely to interfere with study participation or with the ability to complete the study by the judgment of the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Active comparator
    Centralized approach

    Centralized approach managed and coordinated within the BETTER group based at IRCM (Montreal, Quebec), with standardized processes and integrated care pathways. In this approach, scheduling processes and data collection (clinical visits, laboratory analysis, questionnaires) will be handled by the research team. Participants' healthcare professional will be notified (by postal service and/or email if available)

    Behavioral: Centralized Monitoring Approach

  • Active comparator
    Decentralized approach

    In this approach, participants will be monitored by their preferred HCP according to consensus-based guidelines for monitoring pre-clinical T1D which will be communicated to both participants and HCPs. Therefore, follow-up and monitoring will be at the discretion of the HCP. However, regular contacts by the research team according to T1D stages will ensure the actual follow-up received.

    Behavioral: Decentralized Monitoring Approach

Interventions

  • BehavioralCentralized Monitoring Approach

    A semi-annual clinical visit (either by medical or trained staff) will be conducted to collect various data: IAb assessment, HbA1c measure, fasting blood glucose, glucose monitoring and information about eating habits, mental health, menstrual cycle, physical activity.

  • BehavioralDecentralized Monitoring Approach

    Monitored by the participant's preferred local Healthcare Provider (HCP) according to consensus-based guidelines for pre-clinical T1D. The research team does not conduct direct clinical visits; instead, the research team conducts semi-annual phone calls (and initial 1-month or 6-month check-ins depending on T1D stage) to confirm that appropriate HCP follow-up is ongoing, document any clinical assessments conducted by the HCP, and collect the results of those investigations.

06

What researchers measure

Primary outcomes

  1. Feasibility of screening and monitoring outcomes

    Percentage of conversion of eligible participants to consent to participating in the study

    Time frame: Through study completion for positive screened participants: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Feb 2028, 17 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 17 months is below that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → Sep 2026, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Jan 7, 2026
StartActual
Sep 1, 2026was Apr 2026
Primary completionEst.
Feb 1, 2028
CompletionEst.
Mar 31, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 17, 2026
Sites
1 site added — first site in Canada
Show site
  • Institut de recherches cliniques de Montréal · Montreal, Canada
Nov 17, 2026
Start date
Apr 5, 2026→Sep 1, 2026 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Canada
    Show site
    • Institut de recherches cliniques de Montréal · Montreal, Canada
    Start date Apr 5, 2026→Sep 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07322380
Lead sponsor
Institut de Recherches Cliniques de Montreal
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jan 7, 2026
Start date
Sep 1, 2026
Primary completion
Feb 1, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Valérie Boudreau, Ph.D
Contact
valerie.boudreau@ircm.qc.ca
5149703660
Maha Lebbar, M.D.
Contact
maha.lebbar@ircm.qc.ca
Rémi Rabasa-Lhoret, M.D. Ph.D
principal investigator · Institut de Recherches Cliniques de Montreal

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion